摘要
目的系统评价康莱特联合化疗药物胸腔内灌注治疗恶性胸腔积液的疗效和安全性。方法计算机检索Pub Med、EMbase、Cochrane library、中国期刊全文数据库、维普数据库、中国生物医学文献数据库,全面收集康莱特联合化疗药物胸腔内灌注治疗恶性胸腔积液的随机对照试验(RCT),按照纳入与排除标准,提取资料及评价质量,采用Rev Man 5.14统计学软件进行Meta分析。结果共纳入13项RCT,合计537例患者。Meta分析结果显示,治疗组近期有效率更高[RR=1.43,95%CI(1.28,1.59),P<0.01];治疗组生存质量改善率优于对照组[RR=1.51,95%CI(1.09,2.09),P<0.05]。治疗组胃肠道反应、胸痛的发生率显著优于对照组(P<0.01);治疗组肾功能异常、骨髓毒性、发热的发生率与对照组比较,差异无统计学意义。结论康莱特联合化疗药方案较单纯使用化疗药更有效,可提高患者生存质量,并能降低部分毒副作用。但尚需高质量的RCT予以证实。
Objective To evaluate the curative effect and safety of Kanglaite combined with intrapleural infusion of chemotherapy drugs in treatment of malignant pleural effusion. Methods Through computer retrieval of PubMed, EMbase, Cochrane library, Chinese periodical full-text database, VIP database, and Chinese biomedical literature database, a comprehensive collection of randomized controlled trials （RCT） of Kanglaite combined with chemotherapy drug pleural infusion was carried out. According to the inclusion and exclusion criteria, the data were extracted to evaluate the quality, and the statistical software Rev Man 5.14 was used for Meta analysis. Results Total 13 RCTs and 537 patients were included. The Meta analysis results showed that the recent effectiveness in the treatment group was higher [RR = 1.43, 95%CI （1.28, 1.59）; P 〈 0.01], and the improvement of survival in the treatment group was better than that in the control group [RR = 1.51, 95%CI （1.09, 2.09）; P 〈 0.05]. The gastrointestinal tract reaction and the incidence of chest pain in the treatment group were significantly better than those in the control group （P 〈 0.01）; the abnormal renal function, bone marrow toxicity, and fever incidence in the treatment group had no significant difference from those in the control group. Conclusion Kanglaite combined with chemotherapy drugs has better efficacy than simple use of chemotherapy drugs. It can improve the quality of life of patients and reduce some side effects, but it still needs to be verified by high-quality RCT.
出处
《西南国防医药》
CAS
2015年第5期482-484,共3页
Medical Journal of National Defending Forces in Southwest China
